10-Q/A Filing

IOVANCE BIOTHERAPEUTICS, INC. CIK: 1425205 Q2 2012

Filing Information

Form Type	10-Q/A
Accession Number	`0001513160-12-000063`
Period End Date	20120630
Filing Date	20120910
Fiscal Year	2012
Fiscal Period	Q2
XBRL Instance	gnpb-20120630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 48 Income Statement 71 Cash Flow Statement 104 Stockholders Equity 13

Balance Sheet 48 line items

Line Item	Tag	Value	Unit	Period
Property and equipment, accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$5.81K	USD	Point-in-time
Cash and cash equivalents	`Cash`	$510.22K	USD	Point-in-time
Property and equipment, accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$2.70K	USD	Point-in-time
Cash and cash equivalents	`Cash`	$15.74K	USD	Point-in-time
Deposits and prepaid expenses	`PrepaidExpenseAndOtherAssetsCurrent`	$13.86K	USD	Point-in-time
Common Stock Par Value	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Common Stock Par Value	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Deposits and prepaid expenses	`PrepaidExpenseAndOtherAssetsCurrent`	$8.63K	USD	Point-in-time
Common Stock Shares Authorized	`CommonStockSharesAuthorized`	1.80B	shares	Point-in-time
Common Stock Shares Authorized	`CommonStockSharesAuthorized`	1.80B	shares	Point-in-time
Total current assets	`AssetsCurrent`	$24.37K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$524.08K	USD	Point-in-time
Common Stock Shares Issued	`CommonStockSharesIssued`	77.99M	shares	Point-in-time
Property and equipment, net of accumulated depreciation of $5,809 and $2,704	`PropertyPlantAndEquipmentNet`	$25.24K	USD	Point-in-time
Common Stock Shares Issued	`CommonStockSharesIssued`	78.29M	shares	Point-in-time
Property and equipment, net of accumulated depreciation of $5,809 and $2,704	`PropertyPlantAndEquipmentNet`	$28.35K	USD	Point-in-time
Rent Deposit	`DepositsAssetsNoncurrent`	$16.00K	USD	Point-in-time
Rent Deposit	`DepositsAssetsNoncurrent`	$16.00K	USD	Point-in-time
Common Stock Shares Outstanding	`CommonStockSharesOutstanding`	77.99M	shares	Point-in-time
Common Stock Shares Outstanding	`CommonStockSharesOutstanding`	78.29M	shares	Point-in-time
Total assets	`Assets`	$568.43K	USD	Point-in-time
Total assets	`Assets`	$65.61K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$190.05K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$609.27K	USD	Point-in-time
Accrued expenses	`InterestPayableCurrent`	$502.35K	USD	Point-in-time
Accrued expenses	`InterestPayableCurrent`	$221.51K	USD	Point-in-time
Accrued expenses - National Institute of Health	`OtherAccruedLiabilitiesCurrent`	-	USD	Point-in-time
Accrued expenses - National Institute of Health	`OtherAccruedLiabilitiesCurrent`	$616.00K	USD	Point-in-time
12% secured promissory notes	`SecuredPromissoryNotes`	-	USD	Point-in-time
12% secured promissory notes	`SecuredPromissoryNotes`	$1.22M	USD	Point-in-time
7% convertible promissory notes	`ConvertibleNotesPayableCurrent`	$5.00M	USD	Point-in-time
7% convertible promissory notes	`ConvertibleNotesPayableCurrent`	$5.00M	USD	Point-in-time
Derivative liabilities	`DerivativeLiabilitiesCurrent`	$7.94M	USD	Point-in-time
Derivative liabilities	`DerivativeLiabilitiesCurrent`	$8.74M	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$16.68M	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$13.35M	USD	Point-in-time
Common stock, $0.000041666 par value; 1,800,000,000 shares authorized, 78,293,095 and 77,993,591 shares issued and outstanding,respectively	`CommonStockValue`	$3.25K	USD	Point-in-time
Common stock, $0.000041666 par value; 1,800,000,000 shares authorized, 78,293,095 and 77,993,591 shares issued and outstanding,respectively	`CommonStockValue`	$3.26K	USD	Point-in-time
Common shares to be issued with 12% secured promissory notes	`CommonSharesToBeIssuedWith12SecuredPromissoryNotes`	-	USD	Point-in-time
Common shares to be issued with 12% secured promissory notes	`CommonSharesToBeIssuedWith12SecuredPromissoryNotes`	$497.89K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$16.36M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$14.59M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-27.38M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-33.48M	USD	Point-in-time
Total Stockholders' Deficiency	`StockholdersEquity`	$-12.78M	USD	Point-in-time
Total Stockholders' Deficiency	`StockholdersEquity`	$-16.62M	USD	Point-in-time
Total Liabilities and Stockholders' Deficiency	`LiabilitiesAndStockholdersEquity`	$65.61K	USD	Point-in-time
Total Liabilities and Stockholders' Deficiency	`LiabilitiesAndStockholdersEquity`	$568.43K	USD	Point-in-time

Income Statement 71 line items

Line Item	Tag	Value	Unit	Period
Revenues	`SalesRevenueGoodsNet`	-	USD	19 Qtrs
Revenues	`SalesRevenueGoodsNet`	-	USD	1 Quarter
Revenues	`SalesRevenueGoodsNet`	-	USD	2 Qtrs
Share-Based Compensation	`ShareBasedCompensation`	$9.21M	USD	1 Quarter
Share-Based Compensation	`ShareBasedCompensation`	$1.70M	USD	2 Qtrs
Share-Based Compensation	`ShareBasedCompensation`	$9.25M	USD	2 Qtrs
Share-Based Compensation	`ShareBasedCompensation`	$13.86M	USD	19 Qtrs
Share-Based Compensation	`ShareBasedCompensation`	$469.49K	USD	1 Quarter
Operating expenses (including $469,486, $9,211,000, $1,696,712, $9,251,302 and $13,855,121 in share-based compensation costs)	`OperatingCostsAndExpenses`	$11.22M	USD	2 Qtrs
Operating expenses (including $469,486, $9,211,000, $1,696,712, $9,251,302 and $13,855,121 in share-based compensation costs)	`OperatingCostsAndExpenses`	$1.38M	USD	1 Quarter
Operating expenses (including $469,486, $9,211,000, $1,696,712, $9,251,302 and $13,855,121 in share-based compensation costs)	`OperatingCostsAndExpenses`	$10.56M	USD	1 Quarter
Operating expenses (including $469,486, $9,211,000, $1,696,712, $9,251,302 and $13,855,121 in share-based compensation costs)	`OperatingCostsAndExpenses`	$3.63M	USD	2 Qtrs
Operating expenses (including $469,486, $9,211,000, $1,696,712, $9,251,302 and $13,855,121 in share-based compensation costs)	`OperatingCostsAndExpenses`	$23.65M	USD	19 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$3.08M	USD	19 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$1.16M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	-	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	-	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$270.00K	USD	1 Quarter
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	$160.04K	USD	19 Qtrs
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	2 Qtrs
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	2 Qtrs
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	1 Quarter
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	1 Quarter
Total costs and expenses	`OperatingExpenses`	$4.78M	USD	2 Qtrs
Total costs and expenses	`OperatingExpenses`	$10.56M	USD	1 Quarter
Total costs and expenses	`OperatingExpenses`	$11.22M	USD	2 Qtrs
Total costs and expenses	`OperatingExpenses`	$26.89M	USD	19 Qtrs
Total costs and expenses	`OperatingExpenses`	$1.65M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-26.89M	USD	19 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-10.56M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-4.78M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-11.22M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-1.65M	USD	1 Quarter
Change in fair value of derivative liability	`IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments`	$746.57K	USD	19 Qtrs
Change in fair value of derivative liability	`IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments`	$1.93M	USD	1 Quarter
Change in fair value of derivative liability	`IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments`	$-398.56K	USD	1 Quarter
Change in fair value of derivative liability	`IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments`	$-620.24K	USD	2 Qtrs
Change in fair value of derivative liability	`IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments`	$-304.60K	USD	2 Qtrs
Interest expense	`InterestExpense`	-	USD	1 Quarter
Interest expense	`InterestExpense`	$199.28K	USD	2 Qtrs
Interest expense	`InterestExpense`	$350.79K	USD	19 Qtrs
Interest expense	`InterestExpense`	-	USD	2 Qtrs
Interest expense	`InterestExpense`	$110.81K	USD	1 Quarter
Amortization of discount on convertible notes	`AmortizationOfDebtDiscountPremium`	$5.50M	USD	19 Qtrs
Amortization of discount on convertible notes	`AmortizationOfDebtDiscountPremium`	$497.89K	USD	2 Qtrs
Amortization of discount on convertible notes	`AmortizationOfDebtDiscountPremium`	$497.89K	USD	1 Quarter
Amortization of discount on convertible notes	`AmortizationOfDebtDiscountPremium`	-	USD	1 Quarter
Amortization of discount on convertible notes	`AmortizationOfDebtDiscountPremium`	-	USD	2 Qtrs
Private placement costs	`PrivatePlacementCosts`	$1.48M	USD	19 Qtrs
Private placement costs	`PrivatePlacementCosts`	-	USD	2 Qtrs
Private placement costs	`PrivatePlacementCosts`	-	USD	1 Quarter
Private placement costs	`PrivatePlacementCosts`	-	USD	2 Qtrs
Private placement costs	`PrivatePlacementCosts`	-	USD	1 Quarter
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$-304.60K	USD	2 Qtrs
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$-1.32M	USD	2 Qtrs
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$1.32M	USD	1 Quarter
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$-398.56K	USD	1 Quarter
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$-6.59M	USD	19 Qtrs
Net Loss	`NetIncomeLoss`	$-6.10M	USD	2 Qtrs
Net Loss	`NetIncomeLoss`	$-327.28K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-33.48M	USD	19 Qtrs
Net Loss	`NetIncomeLoss`	$-11.52M	USD	2 Qtrs
Net Loss	`NetIncomeLoss`	$-10.96M	USD	1 Quarter
Net Loss Per Share, Basic and Diluted	`EarningsPerShareBasicAndDiluted`	-	USD	1 Quarter
Net Loss Per Share, Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.08	USD	2 Qtrs
Net Loss Per Share, Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.15	USD	1 Quarter
Net Loss Per Share, Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.16	USD	2 Qtrs
Weighted-Average Common Shares Outstanding, Basic and Diluted	`WeightedAverageSharesOutstandingBasicAndDiluted`	78.21M	shares	2 Qtrs
Weighted-Average Common Shares Outstanding, Basic and Diluted	`WeightedAverageSharesOutstandingBasicAndDiluted`	78.29M	shares	1 Quarter
Weighted-Average Common Shares Outstanding, Basic and Diluted	`WeightedAverageSharesOutstandingBasicAndDiluted`	74.07M	shares	1 Quarter
Weighted-Average Common Shares Outstanding, Basic and Diluted	`WeightedAverageSharesOutstandingBasicAndDiluted`	72.95M	shares	2 Qtrs

Cash Flow Statement 104 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-6.10M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-327.28K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-33.48M	USD	19 Qtrs
Net loss	`NetIncomeLoss`	$-11.52M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-10.96M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$36.80K	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$67.18K	USD	19 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$3.10K	USD	2 Qtrs
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	$160.04K	USD	19 Qtrs
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	2 Qtrs
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	2 Qtrs
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	1 Quarter
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	1 Quarter
Fair value of vested stock options and warrants	`StockOptionPlanExpense`	$3.55M	USD	19 Qtrs
Fair value of vested stock options and warrants	`StockOptionPlanExpense`	$384.26K	USD	2 Qtrs
Fair value of vested stock options and warrants	`StockOptionPlanExpense`	$1.65M	USD	2 Qtrs
Fair value of derivative liability recorded upon issuance of warrants	`FairValueOfDerivativeLiabilityRecordedUponIssuanceOfWarrants`	-	USD	2 Qtrs
Fair value of derivative liability recorded upon issuance of warrants	`FairValueOfDerivativeLiabilityRecordedUponIssuanceOfWarrants`	-	USD	2 Qtrs
Fair value of derivative liability recorded upon issuance of warrants	`FairValueOfDerivativeLiabilityRecordedUponIssuanceOfWarrants`	$2.56M	USD	19 Qtrs
Amortization of discount on convertible notes	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	-	USD	2 Qtrs
Amortization of discount on convertible notes	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	-	USD	2 Qtrs
Amortization of discount on convertible notes	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$5.00M	USD	19 Qtrs
Common shares to be issued with 12% promissiory notes	`CommonSharesToBeIssuedWith12PromissioryNotes`	-	USD	2 Qtrs
Common shares to be issued with 12% promissiory notes	`CommonSharesToBeIssuedWith12PromissioryNotes`	$497.89K	USD	2 Qtrs
Common shares to be issued with 12% promissiory notes	`CommonSharesToBeIssuedWith12PromissioryNotes`	$497.89K	USD	19 Qtrs
Private placement costs	`PrivatePlacementCosts1`	-	USD	2 Qtrs
Private placement costs	`PrivatePlacementCosts1`	-	USD	2 Qtrs
Private placement costs	`PrivatePlacementCosts1`	$1.48M	USD	19 Qtrs
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$746.57K	USD	19 Qtrs
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$-304.60K	USD	2 Qtrs
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$-620.24K	USD	2 Qtrs
Common stock issued to officer for services	`CommonStockIssuedToOfficerForServices`	$8.01M	USD	19 Qtrs
Common stock issued to officer for services	`CommonStockIssuedToOfficerForServices`	-	USD	2 Qtrs
Common stock issued to officer for services	`CommonStockIssuedToOfficerForServices`	$8.10M	USD	2 Qtrs
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$548.45K	USD	19 Qtrs
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$65.00K	USD	2 Qtrs
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$50.00K	USD	2 Qtrs
Fair value of common stock transferred to officer and director	`FairValueOfCommonStockTransferredToOfficerAndDirector`	$1.74M	USD	19 Qtrs
Fair value of common stock transferred to officer and director	`FairValueOfCommonStockTransferredToOfficerAndDirector`	$702.04K	USD	2 Qtrs
Fair value of common stock transferred to officer and director	`FairValueOfCommonStockTransferredToOfficerAndDirector`	-	USD	2 Qtrs
Write off of advances to related party	`WriteOffOfAdvancesToRelatedParty`	-	USD	2 Qtrs
Write off of advances to related party	`WriteOffOfAdvancesToRelatedParty`	$50.00K	USD	19 Qtrs
Write off of advances to related party	`WriteOffOfAdvancesToRelatedParty`	-	USD	2 Qtrs
Deposits, prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$24.63K	USD	19 Qtrs
Deposits, prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-5.24K	USD	2 Qtrs
Deposits, prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-947.00	USD	2 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$1.11M	USD	19 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$100.35K	USD	2 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$700.06K	USD	2 Qtrs
Accounts expenses - National Institute of Health	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$616.00K	USD	19 Qtrs
Accounts expenses - National Institute of Health	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	-	USD	2 Qtrs
Accounts expenses - National Institute of Health	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$616.00K	USD	2 Qtrs
Net Cash Used In Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$-1.83M	USD	2 Qtrs
Net Cash Used In Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$-1.96M	USD	2 Qtrs
Net Cash Used In Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$-8.84M	USD	19 Qtrs
Property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	-	USD	2 Qtrs
Property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$16.86K	USD	2 Qtrs
Property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$35.05K	USD	19 Qtrs
Advances to related party	`PaymentsToFundLongtermLoansToRelatedParties`	$50.00K	USD	19 Qtrs
Advances to related party	`PaymentsToFundLongtermLoansToRelatedParties`	-	USD	2 Qtrs
Advances to related party	`PaymentsToFundLongtermLoansToRelatedParties`	$50.00K	USD	2 Qtrs
Net Cash Used In Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-85.05K	USD	19 Qtrs
Net Cash Used In Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	2 Qtrs
Net Cash Used In Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-66.86K	USD	2 Qtrs
Proceeds from the issuance of convertible notes, net	`ProceedsFromConvertibleDebt`	$4.62M	USD	19 Qtrs
Proceeds from the issuance of convertible notes, net	`ProceedsFromConvertibleDebt`	-	USD	2 Qtrs
Proceeds from the issuance of convertible notes, net	`ProceedsFromConvertibleDebt`	-	USD	2 Qtrs
Proceeds from the issuance of secured promissory notes, net	`ProceedsFromIssuanceOfSecuredPromissoryNotesNet`	$1.22M	USD	2 Qtrs
Proceeds from the issuance of secured promissory notes, net	`ProceedsFromIssuanceOfSecuredPromissoryNotesNet`	$1.22M	USD	19 Qtrs
Proceeds from the issuance of secured promissory notes, net	`ProceedsFromIssuanceOfSecuredPromissoryNotesNet`	-	USD	2 Qtrs
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$873.00K	USD	2 Qtrs
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$3.09M	USD	19 Qtrs
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$250.00K	USD	2 Qtrs
Due to director	`IncreaseDecreaseInDueToOfficersAndStockholders`	$18.14K	USD	19 Qtrs
Due to director	`IncreaseDecreaseInDueToOfficersAndStockholders`	-	USD	2 Qtrs
Due to director	`IncreaseDecreaseInDueToOfficersAndStockholders`	-	USD	2 Qtrs
Net Cash Provided By Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$873.00K	USD	2 Qtrs
Net Cash Provided By Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$8.94M	USD	19 Qtrs
Net Cash Provided By Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$1.47M	USD	2 Qtrs
Net Decrease In Cash And Cash Equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$15.74K	USD	19 Qtrs
Net Decrease In Cash And Cash Equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-1.02M	USD	2 Qtrs
Net Decrease In Cash And Cash Equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-494.48K	USD	2 Qtrs
Cash and Cash Equivalents, Beginning of Period	`CashAndCashEquivalentsAtCarryingValue`	$268.56K	USD	Point-in-time
Cash and Cash Equivalents, Beginning of Period	`CashAndCashEquivalentsAtCarryingValue`	$15.74K	USD	Point-in-time
Cash and Cash Equivalents, Beginning of Period	`CashAndCashEquivalentsAtCarryingValue`	$1.29M	USD	Point-in-time
Cash and Cash Equivalents, Beginning of Period	`CashAndCashEquivalentsAtCarryingValue`	-	USD	Point-in-time
Cash and Cash Equivalents, Beginning of Period	`CashAndCashEquivalentsAtCarryingValue`	$510.22K	USD	Point-in-time
Cash and Cash Equivalents, End of Period	`CashAndCashEquivalentsAtCarryingValue`	$268.56K	USD	Point-in-time
Cash and Cash Equivalents, End of Period	`CashAndCashEquivalentsAtCarryingValue`	$15.74K	USD	Point-in-time
Cash and Cash Equivalents, End of Period	`CashAndCashEquivalentsAtCarryingValue`	$1.29M	USD	Point-in-time
Cash and Cash Equivalents, End of Period	`CashAndCashEquivalentsAtCarryingValue`	-	USD	Point-in-time
Cash and Cash Equivalents, End of Period	`CashAndCashEquivalentsAtCarryingValue`	$510.22K	USD	Point-in-time
Derivative liability recorded upon issuance of convertible notes and warrants	`DerivativeLiabilityRecordedUponIssuanceOfConvertibleNotesAndAttachedWarrants`	-	USD	2 Qtrs
Derivative liability recorded upon issuance of convertible notes and warrants	`DerivativeLiabilityRecordedUponIssuanceOfConvertibleNotesAndAttachedWarrants`	-	USD	2 Qtrs
Derivative liability recorded upon issuance of convertible notes and warrants	`DerivativeLiabilityRecordedUponIssuanceOfConvertibleNotesAndAttachedWarrants`	$5.54M	USD	19 Qtrs
Derivative liability recorded as offering cost	`DerivativeLiabilityRecordedAsPrivatePlacementCost`	$824.38K	USD	19 Qtrs
Derivative liability recorded as offering cost	`DerivativeLiabilityRecordedAsPrivatePlacementCost`	$642.30K	USD	2 Qtrs
Derivative liability recorded as offering cost	`DerivativeLiabilityRecordedAsPrivatePlacementCost`	$182.08K	USD	2 Qtrs
Common stock issued for intellectual property	`StockIssued1`	-	USD	2 Qtrs
Common stock issued for intellectual property	`StockIssued1`	$217.41K	USD	19 Qtrs
Common stock issued for intellectual property	`StockIssued1`	-	USD	2 Qtrs
Forgiveness of debt by director, treated as contribution of capital	`DebtInstrumentDecreaseForgiveness`	$18.14K	USD	19 Qtrs
Forgiveness of debt by director, treated as contribution of capital	`DebtInstrumentDecreaseForgiveness`	-	USD	2 Qtrs
Forgiveness of debt by director, treated as contribution of capital	`DebtInstrumentDecreaseForgiveness`	-	USD	2 Qtrs

Stockholders Equity 13 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance, Amount	`StockholdersEquity`	$-12.78M	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquity`	$-16.62M	USD	Point-in-time
Common stock sold in private placement at $1.00 per share, February 2012, Amount	`CommonStockSoldInPrivatePlacementAt1.00PerShareFebruary2012Amount`	$67.92K	USD	2 Qtrs
Common stock issued to consultants for services, Amount	`CommonStockIssuedToConsultantsForServicesAmount`	$50.00K	USD	2 Qtrs
Common shares to be issued with 12% secured promissiory notes	`CommonSharesToBeIssuedWith12SecuredPromissioryNotes`	$497.89K	USD	2 Qtrs
Fair value of vested stock options	`FairValueOfVestedStockOptions`	$1.65M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-6.10M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-327.28K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-33.48M	USD	19 Qtrs
Net loss	`NetIncomeLoss`	$-11.52M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-10.96M	USD	1 Quarter
Ending Balance, Amount	`StockholdersEquity`	$-12.78M	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquity`	$-16.62M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.